Research Article
Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice
Table 3
Glioblastoma patient comorbidities and treatments according to age at diagnosis.
| | Characteristic | Age at diagnosis | P-value1 | | < 65 years | ≥ 65 years | | n = 137 | n = 170 | | n (%) | n (%) |
| | Charlson comorbidity score | | | < 0.0001 | | 0 | 90 (65.7) | 65 (38.2) | | | 1 | 8 (5.8) | 21 (12.4) | | | 2 | 23 (16.8) | 37 (21.8) | | | ≥ 3 | 16 (11.7) | 47 (27.6) | | | Extent of surgery | | | 0.00065 | | Resection | 89 (65.0) | 91 (53.5) | | | Biopsy | 37 (27.0) | 76 (44.7) | | | Unknown | 11 (8.0) | 3 (1.8) | | | Radiation dose | | | 0.00026 | | 60 Gy | 84 (61.3) | 63 (37.1) | | | < 60 Gy | 18 (13.1) | 29 (17.0) | | | Unknown dose | 9 (6.6) | 15 (8.8) | | | No radiotherapy | 26 (19.0) | 63 (37.1) | | | Chemotherapy | | | < 0.0001 | | Temozolomide with or without other agents | 70 (51.1) | 60 (35.3) | | | Non-temozolomide agents only | 30 (21.9) | 16 (9.4) | | | No chemotherapy | 37 (27.0) | 94 (55.3) | | | Standard treatment | 38 (27.7) | 15 (8.8) | < 0.0001 | | No radiation and no chemotherapy | 20 (14.6) | 56 (32.9) | 0.00021 |
|
|
Chi-squared test used to compare characteristics between the two age groups. |
